NANBIOSIS researchers showcased the biomedical research process at VHIR’s first Family Open Day, welcoming over 150 visitors.
Barcelona, October 2026 — Members of the CB-DDT research group and the FVPR/U20 platform of NANBIOSIS took part in the first Family Open Day organised by the Vall d’Hebron Institut de Recerca (VHIR) on 3 October 2026. The event welcomed more than 150 visitors, offering the families of VHIR professionals an opportunity to discover the institution’s research facilities and learn about biomedical science through guided tours and interactive activities.
During the event, researchers from CB-DDT and NANBIOSIS platform FVPR/U20, based at VHIR, presented how a potential therapy progresses through the different stages of biomedical research. Using therapeutic extracellular vesicles as an example, they explained the process from their synthesis and characterisation to their evaluation in preclinical models and the subsequent analysis of biological samples.
The activity provided visitors with an insight into how scientific knowledge is generated and how different research stages contribute to the development and evaluation of potential new therapies. Participants also had the opportunity to take part in a hands-on workshop, discovering laboratory techniques and putting their practical skills to the test.
The Family Open Day brought together several VHIR research groups and support teams, with activities covering topics such as respiratory diseases, cardiovascular research, cancer, diabetes and urology. Dedicated workshops for children, including a scientific bingo and a research-themed escape room, further encouraged younger visitors to explore science.
Through its participation, NANBIOSIS contributed to VHIR’s initiative to bring biomedical research closer to the public, highlighting the importance of scientific outreach and providing families with a first-hand look at the people, facilities and processes behind biomedical innovation.
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
If you want to collaborate with us, visit our Order Request page.
Leading scientists
The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.
Custom solutions
Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities
Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.
Standards of quality
Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.
In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:








